TABLE 5.
Race and other demographic factors associated with neutropenia among docetaxel patients
|
Grade 2 Neutropenia (N = 59) |
Grade 3 Neutropenia (N = 58) |
Grade 4 Neutropenia (N = 138) |
|||||
|---|---|---|---|---|---|---|---|
| N a | OR (95% CI) b | N | OR (95% CI) | N | OR (95% CI) | ||
| Race | |||||||
| White | 48 / 491 | Reference | 44 / 487 | Reference | 116 / 559 | Reference | |
| Black | 8 / 74 | 1.45 (0.60–3.51) | 10 / 76 | 1.71 (0.75–3.93) | 16 / 82 | 0.95 (0.50–1.80) | |
| Other | 3 / 33 | 0.83 (0.22–3.04) | 4 / 34 | 1.49 (0.47–4.79) | 6 / 36 | 0.78 (0.29–2.08) | |
| Age | |||||||
| <55 | 29 / 236 | Reference | 27 / 234 | Reference | 52 / 259 | Reference | |
| 55 to <65 | 8 / 180 | 0.33 (0.13–0.86) | 21 / 193 | 0.81 (0.39–1.68) | 32 / 204 | 0.65 (0.38–1.13) | |
| 65 to <75 | 15 / 136 | 1.66 (0.75–3.69) | 8 / 129 | 0.36 (0.13–0.97) | 39 / 160 | 0.87 (0.48–1.56) | |
| ≥75 | 7 / 46 | 1.74 (0.49–6.12) | 2 / 41 | 0.28 (0.05–1.44) | 15 / 54 | 0.90 (0.39–2.04) | |
| Sex | |||||||
| Female | 41 / 431 | Reference | 37 / 427 | Reference | 74 / 464 | Reference | |
| Male | 18 / 167 | 2.80 (0.80–9.75) | 21 / 170 | 0.92 (0.33–2.54) | 64 / 213 | 1.23 (0.65–2.35) | |
| BMI | |||||||
| 18.5 to <25 | 19 / 191 | Reference | 21 / 193 | Reference | 41 / 213 | Reference | |
| <18.5 | 1 / 13 | 1.04 (0.10–10.71) | 3 / 15 | 1.53 (0.25–9.41) | 4 / 16 | 1.85 (0.48–7.19) | |
| 25 to <30 | 21 / 185 | 0.91 (0.41–1.99) | 13 / 177 | 0.84 (0.36–1.92) | 52 / 216 | 1.69 (1.01–2.83) | |
| 30 to <35 | 16 / 175 | 1.03 (0.47–2.25) | 19 / 178 | 1.45 (0.68–3.09) | 31 / 190 | 1.29 (0.73–2.29) | |
| ≥40 | 2 / 34 | 0.66 (0.13–3.25) | 2 / 34 | 0.73 (0.15–3.55) | 10 / 42 | 2.32 (0.98–5.46) | |
| Ever smoke | |||||||
| False | 37 / 363 | Reference | 33 / 359 | Reference | 76 / 402 | Reference | |
| True | 16 / 186 | 0.97 (0.47–2.01) | 18 / 188 | 0.88 (0.44–1.76) | 58 / 228 | 0.94 (0.59–1.48) | |
a
Reporting as counts of patients in category / sum of patients with no neutropenia and patients in category.
b
All variables included in the multinomial analysis with adjustments for mean treatment dose, number of treatment cycles, and base neutrophil count, prior platinum treatment, prior radiotherapy, and cancer site.